- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.
- Next-week expectancy is positive at 55.85% based on similar historical setup states.
MAZE
NASDAQ
Week ended 24 Jul 2026
Weekly Investor Report
Maze Therapeutics, Inc. Common Stock · Healthcare · Biotechnology
Latest close
27.68 USD
-1.6%
latest week
Weekly setup
Weak trend
The weekly trend is not active. Price is -18.9% below the Trend Line and sits at 36.4% of its 52-week range. The latest completed week returned -1.6%, after a -2.6% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks weakly; valuation is expensive relative to peers. Options positioning is volatility with 61/100 conviction, while the latest news-sentiment score is 52/100. Near-term considerations: volume confirmation is below normal; earnings are due in 13d.
Setup score
34
out of 100
Latest Close
27.68 USD
24 Jul 2026
1W Return
-1.6%
latest completed week
4W Return
-2.6%
short-term follow-through
12W Return
1.9%
quarterly tape
Trend Breadth
61.5%
32 of 52 weeks active
Volume Ratio
0.5x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Activity pressure is weak, so confirmation is not yet broad enough.
- The share remains more than 20% below its 52-week high.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-1.6%
Latest completed week; four-week move -2.6%.
Indicator stack
34/65
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Positive 55.85%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
Options pressure
Volatility
61/100 conviction; expected move 17.7%.
News sentiment
52/100
46 relevant articles in the latest sentiment read.
Event risk
13d
Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -18.9% below the Trend Line and sits at 36.4% of its 52-week range. The latest completed week returned -1.6%, after a -2.6% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.5x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
30 Jan
6 Feb
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.1412-week average 0.16
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure2/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.14Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -2.6% over four weeks, 1.9% over 12 weeks, and 64.6% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year32
Trend breadth61.5%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.28Latest activity-pressure read.
Pressure change128.3%Four-week change in activity pressure.
Leadership-19.19Latest relative-leadership reading.
RS change-7.7%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks weakly; valuation is expensive relative to peers.
Factor week 26 Jul 2026
Financial statements through 31 Dec 2025
Field coverage 85%
Model confidence 81%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength14/100Blend of value, momentum, and quality. Underlying universe rank 87; rank 1 is best.
Value18/100Relative valuation strength. Underlying universe rank 83; rank 1 is best.
Quality1/100Profitability and accounting quality. Underlying universe rank 100; rank 1 is best.
Momentum90/100Medium-term price momentum. Underlying universe rank 11; rank 1 is best.
Growth10/100Revenue and earnings growth. Underlying universe rank 91; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- 76.6x Market value relative to trailing revenue.
- EV / EBITDA
- - Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -8.7% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- -12.0% Gross profit retained from each unit of revenue.
- Operating margin
- -608.4% Operating profit retained from revenue.
- Free-cash-flow margin
- -604.7% Free cash flow generated from revenue.
- Return on invested capital
- -44.7% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- -88.1% Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- -270.2% Latest one-year free-cash-flow growth.
- Piotroski F-score
- 3/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- -9.3% Net share repurchases relative to market value.
- Shareholder yield
- -9.3% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 1.2x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Options positioningVolatility
MAZE shows volatility options pressure with a 61/100 conviction score, put-call volume ratio of 17.00, expected move of 17.7%, and Sharemaestro trend signal inactive.
Conviction61/100
Expected move17.7%
Put/call volume17.00
Insider activity-
No recent insider transactions are stored for this company.
News sentiment52/100
Weighted news tone is neutral across 46 relevant articles.
8 positive · 34 neutral · 4 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings13dNext report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
Options expected move17.7%Nearest-chain priced movement where available.
52-week drawdown-48.4%Distance below the 52-week high.
13-week volatility5.9%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
30 Jan
27 Feb
27 Mar
24 Apr
22 May
19 Jun
24 Jul
Weeks higher11 of 2615 weeks finished lower.
Best week+12.0%Week of 13 Mar.
Worst week-36.7%Week of 27 Mar.
Latest week-1.6%Week of 24 Jul.
Shape of recent returns
Strong gains6
Modest gains5
Flat weeks0
Modest losses7
Sharp losses8
Recent vol5.9%13-week weekly-return volatility.
Base vol10.7%52-week weekly-return volatility.
Up/down split30/22Count of positive and negative weeks in the 52-week window.
Average skew7.5% / -6.6%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorUS Healthcare
4-week rank- / 100
Group average1.3%
Trend breadth51.0%
Trend51.0%active weekly trend signals
MD75.0%positive activity pressure
RS48.0%positive relative leadership
Four-week leaders
IndustryUS Biotechnology
4-week rank- / 100
Group average0.5%
Trend breadth67.0%
Trend67.0%active weekly trend signals
MD72.0%positive activity pressure
RS65.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape34/100
Trend, activity pressure, participation, and risk combine to a 34/100 tape read.
Indicator analysis14/100Latest 12-week confirmation: trend 0/12, activity pressure 2/12, relative leadership 0/12.
Activity pressure 0.14; No reversal markers Next-Week ExpectancyPositive 55.85%Next-week expectancy is positive with a 55.85% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors27/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 86; Small Cap Core rank 88 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Options54/100MAZE shows volatility options pressure with a 61/100 conviction score, put-call volume ratio of 17.00, expected move of 17.7%, and Sharemaestro trend signal inactive.
Volatility · Volatility expansion watch · Expected move 17.7% Sentiment52/100Weighted news tone is neutral across 46 relevant articles.
Maze Therapeutics, Inc. Revenue Breakdown – NASDAQ:MAZE Insiders50/100No recent insider transaction evidence is stored.
Earnings13dNext report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 24 Jul 2026 | 27.68 USD | -1.6% | 34.11 USD | 24.78 USD | 0.28 | -19.19 | 1.5M | Off |
| 17 Jul 2026 | 28.12 USD | -8.0% | 34.59 USD | 24.74 USD | 0.18 | -18.88 | 2.4M | Off |
| 10 Jul 2026 | 30.57 USD | -2.2% | 35.05 USD | 24.70 USD | -0.16 | -15.20 | 3.7M | Off |
| 3 Jul 2026 | 31.26 USD | 10.0% | 35.32 USD | 24.62 USD | -0.57 | -11.21 | 3.1M | Off |
| 26 Jun 2026 | 28.43 USD | 10.7% | 35.67 USD | 24.53 USD | -0.99 | -17.81 | 6.6M | Off |
| 19 Jun 2026 | 25.68 USD | 6.8% | 35.98 USD | 24.47 USD | -1.22 | -28.59 | 3.0M | Off |
| 12 Jun 2026 | 24.05 USD | -0.9% | 36.33 USD | 24.46 USD | -1.28 | -30.97 | 3.1M | Off |
| 5 Jun 2026 | 24.27 USD | -8.3% | 36.62 USD | 24.46 USD | -1.33 | -28.51 | 2.1M | Off |
| 29 May 2026 | 26.46 USD | 2.6% | 36.76 USD | 24.47 USD | -1.36 | -25.27 | 1.8M | Off |
| 22 May 2026 | 25.78 USD | 0.9% | 36.98 USD | 24.44 USD | -1.39 | -24.59 | 2.3M | Off |
| 15 May 2026 | 25.56 USD | -1.8% | 37.13 USD | 24.42 USD | -1.35 | -23.84 | 2.5M | Off |
| 8 May 2026 | 26.03 USD | -4.2% | 37.20 USD | 24.40 USD | -1.27 | -22.12 | 2.6M | Off |
| 1 May 2026 | 27.17 USD | 5.3% | 37.25 USD | 24.38 USD | -1.24 | -13.64 | 3.1M | Off |
| 24 Apr 2026 | 25.81 USD | -8.1% | 37.25 USD | 24.33 USD | -1.20 | -16.07 | 4.6M | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.